Loeys–Dietz Syndrome Type 2 (LDS2): Comprehensive Disease-Characteristics Report

Scope and evidence convention. LDS2 means TGFBR2-related Loeys–Dietz syndrome, not the entire genetically heterogeneous LDS spectrum. Many natural-history and management publications combine LDS genotypes; therefore, every numerical estimate below is labeled LDS2-specific or pan-LDS. Evidence types are identified as human clinical, guideline/expert review, in vitro, or animal-model evidence. Literature was prioritized through 2024; one informative 2025 LDS2 case report is included as a post-cutoff development.

Table: This table condenses the most clinically useful and ontology-relevant facts for Loeys-Dietz syndrome type 2, clearly distinguishing broad-LDS values from LDS2-specific evidence. It is useful as a quick curation aid for disease identity, management, and evidence gaps.

1. Disease information

Definition

LDS2 is an autosomal-dominant, pleiotropic connective-tissue and heritable thoracic aortic disease caused by heterozygous germline pathogenic variants in TGFBR2, encoding transforming growth factor-β receptor type II. Its defining hazard is a diffuse, often tortuous arteriopathy with aneurysm, dissection, and rupture that can occur in childhood and at smaller vessel diameters than in nonsyndromic aortopathy. Craniofacial, skeletal, cutaneous, ocular, gastrointestinal, and allergic manifestations vary markedly. TGFBR2 historically accounts for approximately 55–60% of molecularly diagnosed LDS, although this is a case-series proportion rather than population prevalence. (verstraeten2021loeys–dietzsyndrome pages 1-3, meester2017differencesinmanifestations pages 4-5)

Identifiers and names

• MONDO: MONDO:0012427.
• Causal target: TGFBR2, Ensembl ENSG00000163513, transforming growth factor beta receptor 2. Open Targets reports five supporting disease–target evidence records and literature links including PMIDs 16027248, 16928994, 24486179, 26888179, 29392890, 32048120, 32086639. (OpenTargets Search: Loeys-Dietz syndrome 2-TGFBR2)
• Common names: Loeys–Dietz syndrome type 2; LDS type 2; LDS2; TGFBR2-related Loeys–Dietz syndrome; TGFBR2-related syndromic thoracic aortic aneurysm and dissection.
• OMIM: commonly represented as Loeys–Dietz syndrome 2, 610168; TGFBR2, 190182. These identifiers should be verified against the live OMIM record before production ingestion because OMIM was not directly queried here.
• Orphanet: LDS is generally catalogued at syndrome level rather than consistently by historical numerical subtype; verify the current ORPHA mapping before assigning an LDS2-specific code.
• ICD-10-CM/ICD-11 and MeSH: no reliably specific LDS2 code was established from the retrieved evidence. Use the broad LDS/heritable connective-tissue disorder concept plus manifestation codes—e.g., aortic aneurysm/dissection—rather than implying subtype specificity.

This report synthesizes aggregated disease-level resources, cohorts, reviews, primary experiments, and one case report; it is not based on an individual EHR. The 2025 report describes one six-month-old infant and must not be generalized as cohort evidence. (liu2025anoveltgfbr2 pages 7-8)

2. Etiology, risk, protection, and gene–environment interaction

Causal factor

The necessary primary cause is a heterozygous germline TGFBR2 pathogenic/likely pathogenic variant. TGFBR2 is a transmembrane serine/threonine kinase receptor that complexes with TGFBR1 and normally activates canonical SMAD2/3 and noncanonical MAPK signaling. Most disease-associated substitutions affect conserved residues in the intracellular kinase domain. (takeda2016pathophysiologyandmanagement pages 3-4, cousin2017functionalvalidationreveals pages 9-10)

Genetic risk factors

• A pathogenic TGFBR2 allele is the dominant risk factor; inheritance is autosomal dominant, with 50% transmission probability per pregnancy.
• De novo disease is frequent in pan-LDS experience; intrafamilial variability, incomplete penetrance, and nonpenetrance have been reported. (cousin2017functionalvalidationreveals pages 1-2, meester2017differencesinmanifestations pages 4-5)
• Severe systemic features, arterial tortuosity, hypertelorism, wide scars, small body size, female sex in one high-risk TGFBR2 subgroup, rapid aortic growth, and family history of early dissection influence vascular risk and operative timing. In a review of a 441-patient/228-family cohort, some women with TGFBR2 variants and marked systemic features dissected below 45 mm. (papatheodorou2022geneticsofheritable pages 2-4)
• No reproducible LDS2-specific modifier gene, protective allele, founder mutation, or anticipation phenomenon is established in the retrieved evidence.

Environmental and physiologic modifiers

Environment does not cause LDS2, but hemodynamic load can modify expression. Hypertension, high-intensity or isometric exercise, collision/contact activity, and pregnancy-related volume/hormonal changes plausibly increase wall stress. Smoking and conventional vascular risks should be avoided, although LDS2-specific effect sizes are unavailable. The disorder is neither infectious nor toxin-mediated.

Protective factors

No factor prevents inheritance after conception. Clinically protective measures are early molecular diagnosis, blood-pressure control, avoidance of extreme exertion, serial whole-arterial-tree imaging, and prophylactic repair before dissection. These reduce complications rather than curing the molecular defect. Evidence for superiority of one antihypertensive regimen in LDS2 remains weak. (verstraeten2021loeys–dietzsyndrome pages 8-9, papatheodorou2022geneticsofheritable pages 2-4)

3. Phenotypes

Frequencies are generally pan-LDS, because robust TGFBR2-only denominators are scarce.

The syndrome can substantially affect quality of life through serial imaging and surgery, exercise restrictions, chronic pain/instability, feeding or allergic disease, and fear of dissection. However, no validated LDS2-specific EQ-5D, SF-36, or PROMIS norm was found. Cardiovascular disease remains the principal source of morbidity and mortality. (verstraeten2021loeys–dietzsyndrome pages 11-12, meester2017differencesinmanifestations pages 4-5, verstraeten2021loeys–dietzsyndrome pages 7-8)

4. Genetic and molecular information

Gene and variants

• TGFBR2: chromosome 3p24.1 (often rendered 3p24.1; one secondary text appears to contain a 3q typo), seven coding exons; HGNC symbol TGFBR2. Live HGNC should be consulted for the current numeric HGNC ID.
• Variants are normally heterozygous germline variants. Missense substitutions dominate and cluster in the serine/threonine kinase domain; in one analysis, 91/99 HGMD and 43/44 ClinVar pathogenic missense entries were kinase-domain variants. (cousin2017functionalvalidationreveals pages 9-10)
• Frameshift, nonsense, splice, and in-frame indel variants can occur. Truncating alleles require careful interpretation: cardiovascular disease has particularly been associated with truncations predicted to escape nonsense-mediated decay, while simple haploinsufficiency may not reproduce classic receptor-LDS biology. (verstraeten2021loeys–dietzsyndrome pages 1-3)
• Illustrative variants include p.Gly357Trp, used in knock-in mice; c.1255G>T, p.Val419Leu, functionally validated as loss-of-function; and c.1005_1007delGTA, p.Glu335_Tyr336delinsAsp, reported de novo in a six-month-old infant. (liu2025anoveltgfbr2 pages 7-8, cousin2017functionalvalidationreveals pages 1-2, takeda2016pathophysiologyandmanagement pages 3-4)

Population frequency should be evaluated variant-by-variant in gnomAD. A causal LDS2 allele is expected to be absent or extremely rare, consistent with a severe dominant rare disorder. No universal carrier frequency is established. Somatic variants are not the disease mechanism.

Functional interpretation

For p.Val419Leu, modeling predicted altered ATP-binding/inactive kinase conformations; TGFBR2-deficient HCT116-cell rescue assays showed delayed/reduced SMAD2 phosphorylation and reduced TGF-β-responsive transcription. The authors’ abstract states that the variant “significantly delayed SMAD2 phosphorylation” and “significantly decreased TGF-β-induced gene transcription,” thereby confirming LDS in that patient. This is in-vitro functional evidence, not proof of population penetrance. (cousin2017functionalvalidationreveals pages 1-2, cousin2017functionalvalidationreveals pages 9-10)

Variant classifications must follow ACMG/AMP criteria. A VUS alone should not establish LDS2 or drive irreversible family testing; segregation, phenotype, population frequency, computational evidence, RNA studies where relevant, and validated functional assays may permit reclassification.

Modifiers, epigenetics, and chromosome abnormalities

No validated LDS2 modifier locus, disease-specific methylation signature, histone alteration, recurrent CNV, translocation, inversion, or aneuploidy was identified. Large deletions involving TGFBR2 would require separate interpretation because classic LDS2 is usually sequence-variant mediated.

5. Environmental, lifestyle, and infectious information

There is no infectious agent, occupational exposure, pollutant, radiation exposure, diet, alcohol exposure, or toxin known to initiate LDS2. Lifestyle factors modify mechanical risk, not genotype. Avoid tobacco, uncontrolled hypertension, stimulant/vasoconstrictor exposure where clinically relevant, heavy lifting, maximal isometric strain, collision sports, and exercise to exhaustion. Moderate aerobic activity is usually individualized to aortic dimensions, valve function, blood pressure, and prior repair. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 9-11)

Pregnancy is a major physiologic gene–environment interaction. Pan-LDS estimates in one management synthesis were 11% arterial dissection, mostly aortic, and 2% uterine rupture, with heightened peripartum and early-postpartum vulnerability. These estimates must not be treated as TGFBR2-only risks. (verstraeten2021loeys–dietzsyndrome pages 11-12)

6. Mechanism and pathophysiology

Causal chain

1. Upstream genetic lesion: a heterozygous kinase-domain TGFBR2 variant impairs receptor conformation or catalytic signaling.
2. Cell-autonomous effect: reduced ligand-induced TGFBR1/TGFBR2 canonical signaling, including deficient or delayed SMAD2/3 phosphorylation and transcription, is measurable in engineered cells.
3. Developmental/tissue-context response: receptor dysfunction alters smooth-muscle differentiation, mechanosensing, extracellular-matrix homeostasis, neural-crest-derived craniofacial development, and intercellular feedback.
4. The TGF-β paradox: despite receptor loss-of-function in vitro, diseased aortas can show increased TGF-β ligand, pSMAD2, and noncanonical p38/ERK activity. Proposed explanations include compensatory ligand production, impaired negative feedback, signaling from cells retaining a competent receptor complex, and maladaptive paracrine communication between vascular smooth-muscle cells (VSMCs), fibroblasts, and inflammatory cells. (takeda2016pathophysiologyandmanagement pages 3-4, takeda2018tgfβsignalingrelatedgenes pages 8-10)
5. Downstream tissue failure: VSMC contractile dysfunction, medial degeneration, matrix disorganization/elastin injury, adventitial fibrosis, and inflammation reduce arterial-wall resilience.
6. Clinical manifestation: progressive root and branch-vessel dilatation, tortuosity, aneurysm, dissection, and rupture; disturbed embryonic TGF-β signaling also produces palate, skull, skeletal, and joint phenotypes.

Pathways, cells, and ontology suggestions

• Canonical pathway: TGF-β receptor signaling/SMAD2–SMAD3. Suggested GO: transforming growth factor beta receptor signaling pathway (GO:0007179); SMAD protein signal transduction (GO:0060395).
• Noncanonical pathway: TRAF6–TAK1–p38/JNK and ERK MAPK. Suggested GO: MAPK cascade (GO:0000165).
• Structural biology: VSMC contraction, ECM organization, elastin/contractile unit, mechanotransduction, fibrosis. Suggested GO: extracellular matrix organization (GO:0030198), smooth muscle contraction (GO:0006939), response to mechanical stimulus (GO:0009612).
• Cells: vascular smooth-muscle cell (CL:0000359), fibroblast (CL:0000057), endothelial cell (CL:0000115), neural crest cell (CL:0000333), and leukocyte/CD45-positive inflammatory cells (CL:0000738, broad leukocyte concept).

Tgfbr2^G357W/+ mice had increased aortic pSMAD2, thickened media/adventitia, increased Tgfb1, and abundant CD45+ inflammatory infiltrates. By contrast, postnatal smooth-muscle biallelic Tgfbr2 deletion caused thoracic aneurysm and adventitial fibrosis with increased p38/ERK but not increased pSMAD2, showing that model design and residual signaling competence materially affect the phenotype. (takeda2016pathophysiologyandmanagement pages 3-4, takeda2018tgfβsignalingrelatedgenes pages 8-10)

Molecular profiling and advanced technologies

No mature LDS2-specific clinical transcriptomic, proteomic, metabolomic, lipidomic, methylomic, spatial-transcriptomic, or multi-omic biomarker is validated. Single-cell/iPSC work in TGFBR1-related LDS, not LDS2, has shown lineage-specific contractile and ECM defects and rescue with activin A plus rapamycin; it is mechanistically informative but should not be directly assigned to TGFBR2 disease. LDS2-specific single-cell and spatial studies remain a priority.

7. Anatomical structures affected

• Primary organ/system: cardiovascular system—particularly the aortic root, ascending aorta, arch, descending thoracic and abdominal aorta, and medium/large branch arteries. Cerebral, carotid, vertebral, basilar, ophthalmic, pulmonary, coronary, mesenteric, renal, iliac, and peripheral vessels may be involved.
• Secondary systems: craniofacial skeleton/palate, cervical spine, axial and appendicular skeleton, joints, skin, eyes, gastrointestinal tract, lungs, and immune/allergic compartments.
• Tissue: arterial media and adventitia; connective tissue, smooth muscle, elastic lamellae, ECM, fibroblast-rich adventitia.
• Subcellular compartments: plasma-membrane receptor complex, cytoplasmic SMAD/MAPK signaling machinery, nucleus for transcriptional responses, and extracellular matrix.
• Suggested UBERON: aortic root UBERON:0001519, aorta UBERON:0000947, arterial wall UBERON:0001981, palate UBERON:0001716, cervical vertebral column UBERON:0006072, skin UBERON:0002097. Verify ontology releases before ingestion.
• Disease is generally systemic and not lateralized; scoliosis, clubfoot, strabismus, and individual aneurysms may be asymmetric.

8. Temporal development

LDS2 is a congenital genetic disorder with lifelong risk, although clinical recognition ranges from prenatal/neonatal to adulthood. Craniofacial and skeletal signs may be evident at birth; aortic disease can occur during infancy. Pan-LDS dissection or rupture has been reported as early as three months, and the 2025 LDS2 case demonstrated aortic sinus enlargement at six months. (liu2025anoveltgfbr2 pages 7-8, meester2017differencesinmanifestations pages 4-5)

The course is chronic and variably progressive rather than relapsing-remitting. There is no true remission: successful root replacement removes one high-risk segment but does not eliminate distal arterial disease. Critical periods include rapid childhood growth, rapid documented aortic enlargement, pregnancy, delivery/early postpartum, and the period surrounding major surgery. Early diagnosis creates the principal intervention window.

9. Inheritance and population

• Inheritance: autosomal dominant; offspring risk 50%.
• Penetrance: substantial but not demonstrably complete; may be age-dependent. Nonpenetrance and marked variable expressivity are documented. (cousin2017functionalvalidationreveals pages 1-2, meester2017differencesinmanifestations pages 4-5)
• De novo/germline mosaicism: de novo variants are well recognized. Parental germline mosaicism is biologically possible and should be discussed after an apparently de novo result, but no LDS2-specific recurrence percentage is available.
• Anticipation: not established.
• Founder effects/consanguinity: no established founder allele; consanguinity is not a typical factor in dominant LDS2.
• Prevalence/incidence: unknown for LDS2. The 55–60% figure refers to the fraction of diagnosed LDS attributed to TGFBR2, not population prevalence. (verstraeten2021loeys–dietzsyndrome pages 1-3, meester2017differencesinmanifestations pages 4-5)
• Sex/ethnicity/geography: both sexes and diverse ancestries are affected. No robust sex ratio, ethnic enrichment, or endemic region is established. Ascertainment and access to cardiovascular genetics likely drive apparent geographic differences.

10. Diagnostics

Clinical evaluation and imaging

Diagnosis begins with personal/family history and examination for early thoracic aortic disease, generalized arterial tortuosity, hypertelorism, bifid uvula/cleft palate, craniosynostosis, skeletal/joint signs, translucent skin, and allergic/GI disease. There are no universally accepted purely clinical LDS criteria; molecular confirmation is central. (meester2017differencesinmanifestations pages 4-5)

Recommended baseline studies include:

• Transthoracic echocardiography with aortic-root Z-score/diameter, ascending aorta, valves, and ventricular function.
• CTA or MRA from head to pelvis to identify tortuosity, aneurysms, and dissections outside the echocardiographic field.
• ECG and additional cardiac testing as indicated; these are not diagnostic biomarkers.
• Cervical-spine radiographs, including flexion/extension views when appropriate, before procedures involving neck manipulation.
• Orthopedic, ophthalmic, dental/craniofacial, allergy/immunology, and GI evaluation guided by manifestations.

No blood enzyme assay, circulating protein, metabolite, biopsy, liquid biopsy, or omics signature can confirm LDS2. Histology may show medial degeneration, elastic-fiber fragmentation, fibrosis, and altered TGF-β markers but is neither required nor specific.

Genetic testing

1. Use a heritable thoracic aortic disease multigene panel including at minimum TGFBR2, TGFBR1, SMAD2, SMAD3, TGFB2, TGFB3, FBN1, SKI, COL3A1, ACTA2, MYH11, MYLK, and LOX; contemporary panels may include additional validated HTAD genes.
2. Sequence analysis plus deletion/duplication calling is preferred. Single-gene TGFBR2 testing is reasonable when phenotype or a known familial variant is compelling.
3. WES/WGS is useful after a negative panel, in atypical disease, or where structural/noncoding variation is suspected; genome sequencing is not yet guaranteed to resolve all cases.
4. CMA/karyotype/FISH, mitochondrial DNA, and repeat-expansion testing are not routine for classic LDS2 unless a broader differential indicates them.
5. Test the familial variant in first-degree relatives. Prenatal diagnosis and PGT-M are technically possible once the pathogenic familial allele is known.

Differential diagnosis

• Marfan syndrome/FBN1: ectopia lentis and pronounced dolichostenomelia favor Marfan; bifid uvula, hypertelorism, craniosynostosis, and diffuse tortuous arteriopathy favor LDS. (liu2025anoveltgfbr2 pages 5-7)
• Vascular Ehlers–Danlos/COL3A1: marked tissue/organ fragility and characteristic vEDS phenotype; surgical behavior differs.
• Other LDS genotypes: TGFBR1, SMAD2/3, TGFB2/3, IPO8 and related TGF-β signalopathies.
• Shprintzen–Goldberg/SKI, arterial tortuosity syndrome/SLC2A10, congenital contractural arachnodactyly/FBN2, and nonsyndromic HTAD genes.

11. Outcome and prognosis

Aortic and arterial dissection/rupture are the principal causes of premature death. Cerebral hemorrhage has caused death in young children in pan-LDS reports. Events may occur at aortic diameters as small as 3.7 cm in adults, and prophylactic root surgery does not remove distal-vessel risk. (meester2017differencesinmanifestations pages 4-5, verstraeten2021loeys–dietzsyndrome pages 7-8)

The earliest descriptions overrepresented severe disease. The later 441-patient cohort suggested a more favorable overall profile than historical series, highlighting ascertainment bias and broad expressivity. No reliable LDS2-specific 5-year survival, 10-year survival, life expectancy, annual mortality, disability weight, or validated prognostic calculator was found. (papatheodorou2022geneticsofheritable pages 2-4)

Adverse prognostic factors include prior dissection, rapid aortic growth, strong family history, marked systemic phenotype, hypertelorism, arterial tortuosity, wide scars, small body size in some women, uncontrolled blood pressure, and pregnancy. Favorable outcomes depend on early diagnosis, expert surveillance, timely valve-sparing or composite root surgery, and lifelong distal-vessel monitoring.

12. Treatment and real-world implementation

Medical therapy

There is no approved genotype-correcting or disease-eradicating drug. Current practice uses:

• β-blockers to reduce heart rate, blood pressure, and aortic impulse.
• Angiotensin-II receptor blockers, especially losartan, for antihypertensive and potential TGF-β/RAS-modulating effects; expert targets cited are 2.0 mg/kg/day in children and at least 100 mg/day in adults, as tolerated.
• Combination β-blocker/ARB therapy may be considered when blood pressure and progression warrant it.

Evidence is extrapolated from Marfan trials, LDS animal models, and expert experience; controlled LDS2 efficacy data remain absent. An authoritative review explicitly noted the lack of published evidence proving benefit in TGFBR1/TGFBR2 carriers. (verstraeten2021loeys–dietzsyndrome pages 8-9, papatheodorou2022geneticsofheritable pages 2-4, verstraeten2021loeys–dietzsyndrome pages 9-11)

Suggested NCIt concepts: Beta-Adrenergic Blocker; Angiotensin II Receptor Antagonist; Losartan; Antihypertensive Therapy. Suggested ChEBI: losartan CHEBI:6541; verify release-specific identifiers.

Surgery/intervention

Elective aortic-root replacement—often valve-sparing where anatomy and expertise permit—is the only established way to prevent root dissection. Thresholds are individualized:

• Expert LDS1/2 practice: consider surgery at approximately 4.0 cm in adults.
• Prior AHA/ACC guidance summarized in a 2022 review: ≥42 mm.
• ESC guidance summarized there: ≥45 mm for TGFBR1/TGFBR2.

Lower thresholds may be justified by rapid growth, family history, marked syndromic features, pregnancy plans, small body size, or prior dissection. Root and ascending-aortic replacement may be considered together. Other aneurysms are generally considered for intervention when approximately 2–3 times expected diameter, but anatomy-specific expert judgment is essential. (verstraeten2021loeys–dietzsyndrome pages 8-9, papatheodorou2022geneticsofheritable pages 2-4, verstraeten2021loeys–dietzsyndrome pages 9-11)

Suggested NCIt: Aortic Root Replacement, Valve-Sparing Aortic Root Replacement, Aneurysm Repair, Vascular Surgery.

Supportive care

Physical therapy should preserve conditioning while avoiding joint injury and extreme loading. Orthopedic care addresses scoliosis, clubfoot, instability, low bone density, and pain. Cleft-palate/craniosynostosis care, ophthalmology, dental care, nutrition, allergy/EGID/IBD therapy, and psychosocial support are phenotype-directed. Cervical instability must be communicated to anesthesia and surgical teams. (verstraeten2021loeys–dietzsyndrome pages 9-11, verstraeten2021loeys–dietzsyndrome pages 7-8)

Advanced and experimental therapy

No gene replacement, CRISPR, ASO, siRNA, mRNA, cell therapy, or approved TGF-β-targeted therapy is available. Direct systemic TGF-β inhibition is biologically complicated because signaling may be protective early and harmful later. Preclinical models support RAS modulation, but translation remains incomplete.

ClinicalTrials.gov searches found primarily observational or supportive studies rather than LDS2-specific drug trials: NCT05472519 (immunopathology; completed; n=60), NCT02504853 (food allergy/natural history; recruiting; n=1,800), NCT05980104 (single-session pain “Empowered Relief”; completed; n=92), NCT02213484 (microRNAs in hereditary aortopathy; completed; n=20), NCT01322165 (GenTAC registry; completed; n=3,706), and NCT03440697 (aortopathy/aortic-valve pathogenesis; active, not recruiting; n=3,000). These enroll LDS or related disorders and do not establish an LDS2-specific response rate.

13. Prevention

• Primary prevention: the spontaneous/de novo molecular event cannot presently be prevented. Reproductive options include genetic counseling, PGT-M, chorionic-villus sampling, or amniocentesis after identification of the familial variant.
• Secondary prevention: molecular cascade testing, baseline echocardiography, and head-to-pelvis vascular imaging identify presymptomatic relatives.
• Tertiary prevention: strict blood-pressure management, annual or more frequent echocardiography, serial CTA/MRA, activity modification, and prophylactic surgery prevent dissection and disability.

Expert surveillance recommends echocardiography at least annually, more often with rapid progression; head-to-pelvis MRA/CTA at diagnosis, at one year, then every 2–3 years if stable. Pediatric cervical flexion-extension radiographs may be repeated every 3–5 years when indicated. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8)

Before pregnancy, obtain comprehensive brain-to-abdomen vascular imaging and multidisciplinary counseling. During pregnancy, perform echocardiography at least once per trimester and continue postpartum monitoring; management should occur at a tertiary cardio-obstetric center. (verstraeten2021loeys–dietzsyndrome pages 11-12)

There is no LDS-specific vaccine or infectious prophylaxis. Routine immunization applies.

14. Other species and natural disease

No well-established naturally occurring veterinary equivalent of human TGFBR2-related LDS2 was identified in the retrieved literature. Accordingly, no breed-specific VBO term, veterinary prevalence, zoonotic transmission, or cross-species infectious risk applies. TGFBR2 pathway function is evolutionarily conserved across vertebrates, enabling experimental mouse and zebrafish work, but induced genetic models should not be mislabeled as natural animal disease.

Suggested taxa for experimental annotation: Homo sapiens, NCBI Taxon 9606; Mus musculus, 10090; Danio rerio, 7955. Ortholog identifiers should be taken from current NCBI Gene/Alliance records before database ingestion.

15. Model organisms and experimental systems

Knock-in mouse

Tgfbr2^G357W/+ mice model a human LDS-associated receptor substitution. They reproduce vascular, craniofacial, and skeletal manifestations and show progressive aortopathy, increased aortic pSMAD2/Tgfb1, wall thickening, and CD45-positive inflammation. This model supports the signaling paradox and permits preventive-drug testing. (takeda2016pathophysiologyandmanagement pages 3-4, takeda2018tgfβsignalingrelatedgenes pages 8-10)

Conditional knockout models

Postnatal VSMC-specific biallelic deletion—Myh11-CreERT2;Tgfbr2^fl/fl—produces thoracic aneurysm, marked adventitial fibrosis, and increased ERK1/2/p38 activation without increased pSMAD2. Cranial-neural-crest Tgfbr2 deletion causes palate and calvarial defects. These models identify cell- and developmental-stage-specific receptor requirements. (takeda2016pathophysiologyandmanagement pages 3-4, liu2025anoveltgfbr2 pages 8-9)

Cellular and computational models

TGFBR2-deficient HCT116 cells reconstituted with p.Val419Leu, luciferase reporters, Western blotting, homology modeling, and molecular-dynamics simulations demonstrated reduced canonical signaling and altered kinase conformational dynamics. This combination is useful for VUS adjudication but does not reproduce arterial multicellularity, hemodynamics, or lifelong heterozygosity. (cousin2017functionalvalidationreveals pages 1-2, cousin2017functionalvalidationreveals pages 9-10)

Limitations

• Homozygous conditional loss is mechanistically different from the human heterozygous missense state.
• Mouse vessel geometry, lifespan, and hemodynamics differ from humans.
• Craniofacial and immune phenotypes vary by genetic background.
• Single-cell and iPSC rescue findings presently available for TGFBR1-LDS cannot automatically be generalized to LDS2.
• No model fully captures variant-specific penetrance, pregnancy risk, distal arterial heterogeneity, or human quality-of-life burden.

Recent developments and expert assessment, 2023–2024

The 2023–2024 literature increasingly treats LDS2 within genotype-driven HTAD management, emphasizing molecular testing, complete arterial-tree imaging, body-size/sex/family-history-adjusted operative thresholds, and the dual role of TGF-β signaling rather than a simplistic “excess signaling” model. Reviews published in 2024 stress that hereditary aneurysms occur younger, without conventional risk factors, and can dissect at smaller diameters; early diagnosis, molecular testing, surveillance, blood-pressure reduction, and prophylactic surgery remain the practical standard. LDS2-specific randomized therapy, biomarker, single-cell, and population epidemiology studies were still lacking through 2024.

A post-cutoff January 2025 case report expands the variant spectrum with de novo p.Glu335_Tyr336delinsAsp in a six-month-old infant and reports reduced SMAD2 phosphorylation/transcription in vitro. Its abstract-level conclusion is consistent with prior work, but its designation of LDS2 as the “more aggressive subtype” and its recommended 4.0-cm threshold reflect secondary interpretation and should not supersede individualized guideline care. (liu2025anoveltgfbr2 pages 7-8)

Curatorial conclusions and evidence gaps

1. High-confidence entity: MONDO:0012427 is an autosomal-dominant TGFBR2 disorder with diffuse arteriopathy and multisystem connective-tissue manifestations. (OpenTargets Search: Loeys-Dietz syndrome 2-TGFBR2)
2. High-confidence mechanism: most pathogenic missense variants impair receptor kinase/canonical signaling cell-autonomously; compensatory multicellular signaling creates paradoxical lesional SMAD/MAPK activation. (takeda2016pathophysiologyandmanagement pages 3-4, cousin2017functionalvalidationreveals pages 9-10)
3. High-confidence application: genetic diagnosis, cascade testing, whole-arterial-tree surveillance, antihypertensive therapy, activity modification, and early surgery are real-world standards. (verstraeten2021loeys–dietzsyndrome pages 8-9, papatheodorou2022geneticsofheritable pages 2-4)
4. Moderate/low-confidence quantitative phenotyping: many frequency values—95% root aneurysm, 50% cervical instability, 30% food allergy, 60% GI inflammatory disease, and pregnancy complication percentages—are pan-LDS and must not be stored as LDS2-specific penetrance. (verstraeten2021loeys–dietzsyndrome pages 1-3, verstraeten2021loeys–dietzsyndrome pages 11-12, verstraeten2021loeys–dietzsyndrome pages 7-8)
5. Major unmet needs: LDS2 population prevalence/incidence, prospective variant-specific penetrance, validated circulating/omics biomarkers, controlled ARB/β-blocker trials, genotype-stratified pregnancy outcomes, longitudinal quality-of-life data, and TGFBR2-specific single-cell/spatial maps.

Key source URLs and publication dates

• Loeys et al., Nature Genetics, March 2005, discovery paper: https://doi.org/10.1038/ng1511.
• Gallo et al., Journal of Clinical Investigation, January 2014: https://doi.org/10.1172/JCI69666. (gallo2014angiotensinii–dependenttgfβ pages 13-13)
• Cousin et al., Cold Spring Harbor Molecular Case Studies, July 2017: https://doi.org/10.1101/mcs.a001727. (cousin2017functionalvalidationreveals pages 1-2)
• Meester et al., Annals of Cardiothoracic Surgery, November 2017: https://doi.org/10.21037/acs.2017.11.03. (meester2017differencesinmanifestations pages 4-5)
• Takeda et al., International Journal of Molecular Sciences, July 2018: https://doi.org/10.3390/ijms19072125. (takeda2018tgfβsignalingrelatedgenes pages 8-10)
• Verstraeten, Dietz & Loeys, management chapter, October 2021: https://doi.org/10.1002/9781119432692.ch36. (verstraeten2021loeys–dietzsyndrome pages 8-9)
• Papatheodorou et al., Cardiogenetics, February 2022: https://doi.org/10.3390/cardiogenetics12010006. (papatheodorou2022geneticsofheritable pages 2-4)
• Liu et al., Heliyon, January 2025: https://doi.org/10.1016/j.heliyon.2025.e42116. (liu2025anoveltgfbr2 pages 7-8)

References

1. (OpenTargets Search: Loeys-Dietz syndrome 2-TGFBR2): Open Targets Query (Loeys-Dietz syndrome 2-TGFBR2, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (verstraeten2021loeys–dietzsyndrome pages 1-3): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

3. (takeda2016pathophysiologyandmanagement pages 3-4): Norifumi Takeda, Hiroki Yagi, Hironori Hara, Takayuki Fujiwara, Daishi Fujita, Kan Nawata, Ryo Inuzuka, Yuki Taniguchi, Mutsuo Harada, Haruhiro Toko, Hiroshi Akazawa, and Issei Komuro. Pathophysiology and management of cardiovascular manifestations in marfan and loeys-dietz syndromes. International heart journal, 57 3:271-7, May 2016. URL: https://doi.org/10.1536/ihj.16-094, doi:10.1536/ihj.16-094. This article has 85 citations and is from a peer-reviewed journal.

4. (meester2017differencesinmanifestations pages 4-5): Josephina A. N. Meester, Aline Verstraeten, Dorien Schepers, Maaike Alaerts, Lut Van Laer, and Bart L. Loeys. Differences in manifestations of marfan syndrome, ehlers-danlos syndrome, and loeys-dietz syndrome. Annals of Cardiothoracic Surgery, 6:582-594, Nov 2017. URL: https://doi.org/10.21037/acs.2017.11.03, doi:10.21037/acs.2017.11.03. This article has 409 citations.

5. (takeda2018tgfβsignalingrelatedgenes pages 8-10): Norifumi Takeda, Hironori Hara, Takayuki Fujiwara, Tsubasa Kanaya, Sonoko Maemura, and Issei Komuro. Tgf-β signaling-related genes and thoracic aortic aneurysms and dissections. International Journal of Molecular Sciences, 19:2125, Jul 2018. URL: https://doi.org/10.3390/ijms19072125, doi:10.3390/ijms19072125. This article has 181 citations.

6. (cousin2017functionalvalidationreveals pages 9-10): Margot A. Cousin, Michael T. Zimmermann, Angela J. Mathison, Patrick R. Blackburn, Nicole J. Boczek, Gavin R. Oliver, Gwen A. Lomberk, Raul A. Urrutia, David R. Deyle, and Eric W. Klee. Functional validation reveals the novel missense v419l variant in tgfbr2 associated with loeys–dietz syndrome (lds) impairs canonical tgf-β signaling. Cold Spring Harbor Molecular Case Studies, 3:a001727, Jul 2017. URL: https://doi.org/10.1101/mcs.a001727, doi:10.1101/mcs.a001727. This article has 10 citations and is from a peer-reviewed journal.

7. (cousin2017functionalvalidationreveals pages 1-2): Margot A. Cousin, Michael T. Zimmermann, Angela J. Mathison, Patrick R. Blackburn, Nicole J. Boczek, Gavin R. Oliver, Gwen A. Lomberk, Raul A. Urrutia, David R. Deyle, and Eric W. Klee. Functional validation reveals the novel missense v419l variant in tgfbr2 associated with loeys–dietz syndrome (lds) impairs canonical tgf-β signaling. Cold Spring Harbor Molecular Case Studies, 3:a001727, Jul 2017. URL: https://doi.org/10.1101/mcs.a001727, doi:10.1101/mcs.a001727. This article has 10 citations and is from a peer-reviewed journal.

8. (papatheodorou2022geneticsofheritable pages 2-4): Efstathios Papatheodorou, Dimitrios Degiannis, and Aris Anastasakis. Genetics of heritable thoracic aortic disease. Cardiogenetics, 12:63-79, Feb 2022. URL: https://doi.org/10.3390/cardiogenetics12010006, doi:10.3390/cardiogenetics12010006. This article has 14 citations.

9. (verstraeten2021loeys–dietzsyndrome pages 8-9): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

10. (verstraeten2021loeys–dietzsyndrome pages 7-8): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

11. (verstraeten2021loeys–dietzsyndrome pages 9-11): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

12. (verstraeten2021loeys–dietzsyndrome pages 11-12): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

13. (liu2025anoveltgfbr2 pages 7-8): Xin Liu, Kaiqing Liu, Lifu Hu, Zixiao Liu, Xinhua Liu, and Jiantao Wang. A novel tgfbr2 mutation causes loeys-dietz syndrome in a chinese infant: a case report. Heliyon, Jan 2025. URL: https://doi.org/10.1016/j.heliyon.2025.e42116, doi:10.1016/j.heliyon.2025.e42116. This article has 1 citations.

14. (liu2025anoveltgfbr2 pages 5-7): Xin Liu, Kaiqing Liu, Lifu Hu, Zixiao Liu, Xinhua Liu, and Jiantao Wang. A novel tgfbr2 mutation causes loeys-dietz syndrome in a chinese infant: a case report. Heliyon, Jan 2025. URL: https://doi.org/10.1016/j.heliyon.2025.e42116, doi:10.1016/j.heliyon.2025.e42116. This article has 1 citations.

15. (liu2025anoveltgfbr2 pages 8-9): Xin Liu, Kaiqing Liu, Lifu Hu, Zixiao Liu, Xinhua Liu, and Jiantao Wang. A novel tgfbr2 mutation causes loeys-dietz syndrome in a chinese infant: a case report. Heliyon, Jan 2025. URL: https://doi.org/10.1016/j.heliyon.2025.e42116, doi:10.1016/j.heliyon.2025.e42116. This article has 1 citations.

16. (gallo2014angiotensinii–dependenttgfβ pages 13-13): Elena M. Gallo, David C. Loch, Jennifer P. Habashi, Juan F. Calderon, Yichun Chen, Djahida Bedja, Christel van Erp, Elizabeth E. Gerber, Sarah J. Parker, Kimberly Sauls, Daniel P. Judge, Sara K. Cooke, Mark E. Lindsay, Rosanne Rouf, Loretha Myers, Colette M. ap Rhys, Kathleen C. Kent, Russell A. Norris, David L. Huso, and Harry C. Dietz. Angiotensin ii–dependent tgf-β signaling contributes to loeys-dietz syndrome vascular pathogenesis. Journal of Clinical Investigation, 124(1):448-460, Dec 2014. URL: https://doi.org/10.1172/jci69666, doi:10.1172/jci69666. This article has 325 citations and is from a highest quality peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.